Hidradenitis Suppurativa and Cancer: Is There a Connection?

Hidradenitis Suppurativa and Cancer

Hidradenitis Suppurativa: A Horrible Disease Afflicting Millions Worldwide

TrialSite News has been actively covering the serious skin disease and potential autoimmune-related disorder Hidradenitis Suppurativa (HS). Anywhere from 1 to 4 % of the developed world’s population struggles with what can be an extremely painful and debilitating disease. There is no cure, and many are treated with powerful immunosuppressive medications such as Humira. TrialSite News traffic is growing to the point of an emerging Patient Network. Many within this viewer network have identified that they struggle with HS. Recently, many in our HS network shared feedback and comments about our posting of recent positive Phase 2 bermekimab results. We believe that potentially 200,000 or more in the U.S. may struggle with HS. The consequences of HS are severe: it produces a chronic, painful and debilitating effect on many patients with moderate to severe cases.  People with HS suffer from greater pain and associated psychological comorbidities, including depression, anxiety, disability, and impairments in quality of life compared to those with other dermatologic conditions. As if that wasn’t bad enough,...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee